Core Insights - SBC Medical Group Holdings has completed the purchase of 5 Bitcoin (BTC) as part of its strategic financial policy aimed at enhancing long-term corporate value and responding to macroeconomic fluctuations [1][2] - The acquisition of Bitcoin is viewed as a means to preserve asset value, particularly during inflationary periods, and to improve financial stability through diversified investments [1] - The company emphasizes adherence to asset diversification and prudent financial management within a robust risk management framework [1] Details of BTC Purchase - Purchased Cryptocurrency: Bitcoin (BTC) [2] - Purchase Amount: 5 BTC (approximately ¥60 million / US$0.4 million) [2] - Purchase Date: April 14, 2025 [2] Company Overview - SBC Medical is headquartered in Irvine, California, and Tokyo, Japan, focusing on providing management services and products to cosmetic treatment centers [3] - The company offers comprehensive management services to franchise clinics, including advertising, staff management, customer booking, housing assistance, construction, medical equipment procurement, and IT solutions [3]

Company Overview - SBC Medical Group Holdings Incorporated is a global franchise and provider of services for aesthetic clinics, headquartered in Irvine, California, and Tokyo, Japan [7] - The company focuses on providing comprehensive management services to franchisee clinics, including advertising, staff management, booking reservations, employee housing assistance, clinic construction, medical equipment procurement, and IT software solutions [7] Upcoming Event - SBC Medical has been invited to present at the Emerging Growth Conference on April 17, 2025, at 9:05 AM Eastern time for a duration of 30 minutes [1][3] - The event will allow existing shareholders and the investment community to interact with the Company's CFO, Yuya Yoshida, in real time [2][3] - Attendees can submit questions in advance or ask during the event, with the CFO aiming to address as many as possible [3] Conference Details - The Emerging Growth Conference is designed for public companies to present new products, services, and major announcements efficiently [5] - The conference will cover a wide range of growth sectors and is expected to attract tens of thousands of individual and institutional investors, as well as investment advisors and analysts [6] - All sessions will be conducted through video webcasts, and an archived version will be available for those unable to attend live [4][6]

SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employe ...

As the aesthetic medical market continues to mature, SBC Medical is actively advancing a multi-branding strategy to address increasingly segmented consumer needs. "SBC NEO Skin Clinic" represents a strategic shift from conventional surgical aesthetic procedures to non-invasive dermatological treatments, unlocking new growth opportunities within SBC's business model. The brand is also positioned to capture demand from consumers who previously sought aesthetic treatments abroad, particularly in South Korea, b ...

SBC Medical Group Holdings (SBC) Q4 2024 Earnings Call March 28, 2025 12:56 PM ET Moderator Good morning. I'm Fukui, SBC's IR office head. It It is time to start, so we would like to start. Thank you very much for attending SBC Medical Group Holdings Financial Results Briefing despite your busy schedules. Today, we have Mr. Aikawa, the CEO and Guy, the Vice President, and will be explaining the financial results and outlook. On the right hand side, there is a QA box. So if you do have a question, please wri ...

Service Contracts and Consulting - The company entered into service contracts with Medical Corporation Association Furinkai and Junikai for operational and management consulting services, with fees of JPY 60,000,000 and JPY 1,700,000 per month respectively [54][60]. - The effective period for the service contracts with Furinkai is from September 1, 2024, to August 31, 2027, while the contract with Junikai is from September 1, 2023, to August 31, 2027 [58][61]. - The company provides consulting services focused on customer acquisition, operational efficiency, and development of new treatment methods in cosmetic dermatology [57][62]. - The company’s consulting services include training for medical facility employees and support for the implementation of business systems [58][62]. Revenue and Financial Performance - Franchising revenue increased to $61,033,032 in 2024 from $42,103,380 in 2023, representing a growth of approximately 44.9% [103]. - Procurement revenue rose slightly to $54,814,399 in 2024 compared to $53,186,662 in 2023, indicating a growth of about 3.1% [103]. - Management services revenue decreased to $53,113,155 in 2024 from $72,282,549 in 2023, reflecting a decline of approximately 26.5% [103]. - Total revenues for the company reached $205,415,542 in 2024, up from $193,542,423 in 2023, marking an increase of about 6.5% [103]. - The Company generated over 90% of its revenue from management services to Medical Corporations (MCs) under franchise agreements, totaling $195,173,889 for the year ended December 31, 2024, compared to $182,738,049 in 2023, representing an increase of approximately 6.4% [144][145]. Customer Engagement and Satisfaction - The company has developed a customer rewards program with three tiers: silver, gold, and diamond, incentivizing customer loyalty through points that can be redeemed for discounts [81]. - The franchisee clinics have an average repeat customer rate of over 71%, with a total of over 6.0 million customers globally in 2024 [105]. - The patient base at franchisee clinics increased from 3.0 million in 2021 to approximately 3.9 million in 2024, reflecting a growing demand for cosmetic procedures [112]. - The average repeat customer rate and patient satisfaction are key indicators of the company's success and brand awareness in the cosmetic medical service industry [112]. Market Expansion and New Products - The company plans to pursue a disciplined new clinic growth strategy, aiming to increase the number of franchisee clinics to enhance revenue generation [109]. - New product launches included the "Medical-sized diet" and "Shonan Beauty Dermatology" clinics, expanding the service offerings [226]. - The company is focusing on market expansion with new clinics established in various locations, including Itaewon and Shonan [226]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and enhance service capabilities [226]. Technology and Innovation - The company utilizes advanced technologies, including AI and simulation technology, to enhance training and operational efficiency at franchisee clinics [87]. - The integration of advanced technologies, such as 5G/6G, allows for remote operations and consultations, improving patient safety and care [106]. - The company is exploring potential mergers and acquisitions to strengthen its product portfolio, with potential targets identified in the cosmetic surgery sector [229]. - The company is leveraging advanced technology to ensure proper procedure adherence and improve patient outcomes [233]. Compliance and Regulatory Environment - The company is subject to extensive government regulations globally, which could impact operations if licenses or permits are not obtained or retained [153]. - The company must obtain prior consent from customers before transferring sensitive personal data, such as medical records, as mandated by the APPI [162]. - The company is required to comply with the Law on Medical Examination and Treatment No. 15/2023/QH15, defining rights and obligations related to health diagnosis and treatment [191]. - The company is subject to various laws and regulations in Japan, including the Act on the Protection of Personal Information (APPI), which imposes requirements on the handling of personal data [160]. Internal Controls and Risk Management - The Company recorded a misappropriation loss of $409,030 for the year ended December 31, 2023, due to funds misappropriated by a former manager, totaling approximately JPY632 million ($5.6 million) since 2012 [146][148]. - The Company is implementing changes to strengthen internal controls, including hiring personnel with accounting experience and establishing a project to document processes and assess fraud risks [151][154]. - The Company has identified material weaknesses in its internal control environment and is taking steps to address these issues to prevent future misappropriations [150][152]. Patents and Intellectual Property - The Company holds registered patents and trademarks in Japan, with a significant number of applications filed with the International Bureau of the World Intellectual Property Organization [216]. - The Company has filed numerous trademark applications in Japan, with several notable trademarks listed [225]. - The company has pending applications for several new technologies, including "Aging Lift" and "Jade Skin Dermapen," which are expected to enhance service offerings [228]. - The company has filed multiple patent applications in Japan related to aesthetic medicine and treatment methods, specifically JP2023-136790 and JP2023-136792 [1]. Future Outlook and Strategic Initiatives - The company provided an optimistic outlook for Q4 2023, projecting revenue growth of 15% to 18% [229]. - Future guidance includes an expected EBITDA margin improvement of 5% by the end of 2024 [229]. - The company is committed to ongoing research and development to enhance treatment effectiveness and patient safety [8]. - The company aims to leverage its existing data infrastructure to support new acquisitions, enhancing overall market competitiveness [243].

Exhibit 99.1 SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results Irvine, California, U.S.A., March 28, 2025 (Business Wire) — SBC Medical Group Holdings Incorporated (NASDAQ: SBC, "SBC Medical" or the "Company"), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for - the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Full Year 2024 H ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 88-1192288 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 200 Spectrum Center Dr. STE 300 Irvine, CA 92618 (Address of principal executive offices) (Zip Code) Title of each class Trading Symbol(s) Name of each exchange on Which Registered Common Stock, $0.0001 par value per share SBC The Nasdaq Stock Market LLC Redeemable Warrants, each whole warrant exercisable for one sh ...

Revenue Growth - Total revenues for Q3 2024 were $53 million, a 12% increase from $47 million in Q3 2023[2] - Total revenues for the nine months ended September 30, 2024 were $160 million, representing a 23% increase from $131 million in the same period of 2023[10] - Total revenues for the three months ended September 30, 2024, were $53,084,883, an increase of 12% compared to $47,278,685 for the same period in 2023[26] Net Income and Profitability - Net income for Q3 2024 was $2 million, down from $8 million in Q3 2023, while net income for the nine months was $40 million, a 60% increase from $25 million in the same period of 2023[4][5] - Net income attributable to SBC Medical Group Holdings Incorporated for the three months ended September 30, 2024, was $2,832,894, down from $8,356,414 in the same period last year[26] - Comprehensive income attributable to SBC Medical Group Holdings Incorporated for the nine months ended September 30, 2024, was $41,575,160, compared to $5,626,457 in the prior year[26] - Basic and diluted net income per share for the three months ended September 30, 2024, was $0.03, a decrease from $0.09 in the same period of 2023[26] - Net income for September 2024 was $40,142,008, a 64.5% increase from $24,330,964 in September 2023[27] EBITDA and Operating Performance - EBITDA for the nine months ended September 30, 2024 was $68 million, a 21% increase from the same period in 2023, with an EBITDA margin of 42%[4] - EBITDA for the three months ended September 2024 was $14,852,962, with an EBITDA margin of 28%, compared to $23,311,051 and 49% in the same period of 2023[29] - Income from operations for the three months ended September 30, 2024, was $13,834,603, down from $20,023,242 in the same period last year[26] Operating Expenses - Operating expenses for the three months ended September 30, 2024, totaled $29,404,487, significantly higher than $13,475,134 for the same period in 2023[26] - Total operating expenses for the nine months ended September 30, 2024, were $56,592,092, compared to $47,265,904 in the previous year[26] Customer and Clinic Growth - The number of partner clinics increased to 224 as of September 30, 2024, up by 24 from the previous year[5] - The number of customers in the last twelve months reached 4.3 million, reflecting a year-over-year increase of 13.5%[6] Cash and Liquidity - Cash and cash equivalents totaled $137.4 million as of September 30, 2024, up from $103 million at the end of 2023[13] - Net cash provided by operating activities was $27 million for the nine months ended September 30, 2024, a 23% increase from $22 million in the same period of 2023[14] - Cash and cash equivalents at the end of the period reached $137,393,070, up from $77,430,969 a year earlier, indicating a 77.4% increase[28] - Net cash provided by operating activities increased to $27,886,231 in September 2024 from $22,753,983 in September 2023, representing a 22.5% growth[27] Balance Sheet and Assets - Total assets increased to $296,478,592 as of September 30, 2024, up from $258,805,271 on December 31, 2023, representing a growth of approximately 14.5%[23] - Current assets rose to $202,099,828, compared to $165,905,926, reflecting an increase of about 21.7%[23] - Total stockholders' equity reached $205,520,424, a significant increase from $143,810,249, marking an increase of approximately 43%[24] - Retained earnings improved to $182,923,786, up from $142,848,732, indicating a growth of around 28%[24] - Current liabilities decreased to $72,420,534 from $92,451,270, a reduction of about 21.7%[23] - Non-current liabilities fell to $18,537,634, down from $22,543,752, representing a decrease of approximately 17.7%[23] Investments and Other Financial Metrics - Long-term investments increased significantly to $4,905,115 from $849,434, marking a growth of approximately 478%[23] - The company reported a realized gain on short-term investments of $1,682,282 in September 2024, compared to a loss of $223,164 in September 2023[27] - The company made a significant investment in customer loans receivable, totaling $12,860,220 in September 2024[27] - Cash paid for income taxes was $31,332,123 in September 2024, compared to $12,608,072 in September 2023, reflecting a substantial increase in tax obligations[28] - The company reported a net cash used in investing activities of $(5,554,039) in September 2024, contrasting with a net cash provided of $8,659,196 in September 2023[28] - Proceeds from reverse recapitalization amounted to $11,707,417 in September 2024, indicating a strategic move to enhance capital structure[28] Return on Equity - Return on equity for the nine months ended September 30, 2024 was 31%, a year-over-year increase of one percentage point[7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-41462 PONO CAPITAL TWO, INC. (Exact name of registrant as specified in its charter) | --- | --- | |--------- ...